Healthcare / BiotechnologyNasdaqCM
$5.35
-0.35 (-6.14%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-80.9M · quality 62.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$33M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-45.2%
↓Gross Margin
N/A
•Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-3794.1%
FCF / Net income
3.43x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.2M · net income $-24.2M · FCF $-82.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $2.2M | $2.2M | $3.9M | $15.5M | $13.9M | $0.00 | $0.00 | — |
| Net Income | $-24.2M | $-24.2M | $-131.2M | $-87.7M | $-96.0M | $-128.3M | $-108.5M | $-52.3M |
| EBITDA | $-85.2M | $-85.2M | $-86.5M | $-85.1M | $-93.9M | — | — | — |
| EPS | — | — | -20.94 | -34.20 | -56.25 | — | — | — |
| Operating Margin | -4024.9% | -4024.9% | -2259.9% | -567.5% | -701.7% | — | — | — |
| Net Margin | -1106.7% | -1106.7% | -3326.0% | -564.6% | -690.6% | — | — | — |
| Balance Sheet | ||||||||
| Debt/Equity | 0.10 | 0.10 | -0.29 | 0.12 | 0.12 | — | — | — |
| Current Ratio | 2.56 | 2.56 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-82.9M | $-82.9M | $-80.9M | $-79.0M | $-80.3M | $-116.6M | $-76.3M | $-49.6M |
| Returns | ||||||||
| ROE | -45.2% | -45.2% | 452.9% | -95.2% | -92.4% | -69.5% | -49.3% | 80.5% |
| Valuation | ||||||||
| P/B | 0.62 | 0.62 | — | 0.49 | 0.54 | — | — | — |
| Growth & Yield | ||||||||
| Revenue Growth | -44.6% | -44.6% | -74.6% | 11.7% | — | — | — | — |
| EPS Growth | — | — | 38.8% | 39.2% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+1.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-20.94 → n/d
Residual
+1.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.